Navigation Links
Stem Cell Therapy - A Solution for Parkinson's disease
Date:10/23/2013

LA JOLLA, Calif., Oct. 23, 2013 /PRNewswire/ -- "Stem cell therapy is an enthralling new achievement for the management of Parkinson's disease," said Dr. Stacy, the Vice Dean for Clinical Research, Neurology at Duke University School of Medicine.

According to the Michael J. Fox Foundation, Parkinson's disease in the U.S. alone affects one in 100 people over 60 and 60,000 new cases will be diagnosed this year. Additionally, today's best Parkinson's drug was discovered in 1967.

Fast forward to 2013, stem cells offer a window into brain degenerating Parkinson's disease (PD). Scientists have found stem cells to be especially promising for treating rapidly-progressing diseases. Current findings propose that stem cells are appropriate in the management of neurodegenerative disorders.

Adipose-derived adult stem (ADAS) cells are the multipotent cells and precursors for the important cells of the central nervous system. Researchers have found that these stem cells self-renew and provide a therapeutic effect by differentiating into dopaminergic neurons and expressing neurotrophic factors e.g. brain-derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF). All these facilitate protection of the nigrostriatal system thus offering a revolutionary and new prospect for the treatment of Parkinson's disease, particularly in cases where existing dopamine-replacement approaches remain unsuccessful to satisfactorily combat the symptoms.  (PD is the result of loss of dopamine-generating cells in the nigrostriatal system).

Kitada M and Dezawa M, the two prominent researchers of Tohoku University Graduate School of Medicine, Sendai, Japan, noted that cell transplantation holds a great potential for treating Parkinson's disease, and numerous other diseases. According to them, the stem cells are easily accessible and are devoid of serious technical and ethical problems and are the appropriate candidates for transplantation.  Stem cell therapy is a unique way to repair or replace the damaged or dead cells in the disease process, and re-establish cell function and alleviate symptoms.  Thus, such cells may bring about improvement in clinical manifestations of neurodegenerative diseases and neural injuries.

StemGenex® a leading independent U.S. based company has observed researcher's findings to be accurate while working with patients diagnosed with Parkinson's disease. StemGenex provides access to promising treatment for Parkinson's disease via adipose-derived stem cells.  The majority of patients with PD who have undergone this therapy are progressively reporting a reduction of their symptoms and improvement of their quality of living.

StemGenex® is recognized for its service to health, including its function in laying the basis for innovative treatments for Parkinson's disease, Alzheimer's disease, Multiple Sclerosis, Autoimmune diseases, and COPD. It is determined on providing the therapeutic applications of stem cells. New studies and clinical trials are under consideration by the company for the human well-being and health.

To find out more information on adipose stem cell treatments for Parkinson's disease contact StemGenex at 800-609-7795.

Contact@StemGenex.com

http://www.StemGenex.com

Related Links:
Stem Cell Treatments 
Contact StemGenex

 

Video with caption: "Stem Cell Therapy - A Solution For Parkinson's Disease A Computer Graphic visualization of a Brain cell synapse showing chemical messengers or neurotransmitters released from pre-synaptic neuron to be received by the post-synaptic nerve cell receptor." Video available at:  http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-MM02678-20131023-03.mp4 

Image with caption: "Adipose-derived adult stem (ADAS) cells are the multipotent cells and precursors for the important cells of the central nervous system. Researchers have found that these stem cells self-renew and provide a therapeutic effect by differentiating into dopaminergic neurons and expressing neurotrophic factors e.g. brain-derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF). All these facilitate protection of the nigrostriatal system thus offering a revolutionary and new prospect for the treatment of Parkinson's disease, particularly in cases where dopamine-replacement approaches remain unsuccessful to satisfactorily combat the symptoms. (PD is the result of loss of dopamine-generating cells in the nigrostriatal system)." Image available at: http://photos.prnewswire.com/prnh/20131023/MM02678-a

Image with caption: "What is Parkinson's Disease? Parkinson's disease is a chronic progressive neurological disease that affects nerve cells (neurons) in an area of the brain known as the substantia nigra. When healthy these cells normally produce dopamine, a chemical (neurotransmitter) which transmits signals between areas in the brain. This chemical coordinates smooth and balanced muscle movement. Parkinson's disease causes these nerve cells to die, and as a result, body movements are affected." Image available at: http://photos.prnewswire.com/prnh/20131023/MM02678-b

 


'/>"/>
SOURCE StemGenex
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Pets Best Insurance Announces Stem Cell Therapy and Regenerative Veterinary Medicine by Vet-Stem, Inc. Covered by Their Pet Health Insurance
2. Topical BioMedics, Inc., Signs on With CVS Pharmacy; Topricin® Foot Therapy Cream to be Carried in the Retailer’s Foot Care Section
3. Animal Rehabilitation and Wellness Center Gives Castle Rock Golden Retriever a Second Chance to Enjoy Life with Stem Cell Therapy
4. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
5. The Arrow Group of Animal Hospitals in Central Arizona Partners with Vet-Stem, Inc. to Bring Stem Cell Therapy to Their Patients
6. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
7. Fisher BioServices Intensifies Commitment for Cell Therapy Companies in Clinical Trials and Approaching Commercialization
8. Advanced Care Veterinary Services Proves Stem Cell Therapy May Be the Best Weapon in Fighting Pet Pain Due to Arthritis
9. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
10. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
11. Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Discusses Prostate Cancer Stage vs. Gleason Score
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb 22, 2017 Dublin ... the "Global Biological Crop Protection (Bio-Pesticide) Market-By Type, By Application, ... report to their offering. ... Global Biological Crop Protection Market is forecasted to ... The strong growth in biopesticide or biological crop protection market is ...
(Date:2/22/2017)... ... February 22, 2017 , ... NDA ... PhD, MD former Acting Deputy Director in the FDA CDRH Division of Cardiovascular, ... has joined the company as an Expert Consultant. , In Dr. Spyker’s accomplished ...
(Date:2/22/2017)... RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017  United ... announced its financial results for the fourth quarter ... annual 2016 financial results reflect continued growth as ... $700 million," said Martine Rothblatt, Ph.D., United Therapeutics, ... strengthen our ability to develop and advance our ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... organizations to build connected digital health applications, announced a partnership with Redox, a ... to seamlessly connect to many clinical systems while keeping data secure in the ...
Breaking Biology Technology:
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
Breaking Biology News(10 mins):